{
    "clinical_study": {
        "@rank": "161498", 
        "acronym": "REVRI", 
        "arm_group": {
            "arm_group_label": "Lenalidomide & Rituximab", 
            "arm_group_type": "Experimental", 
            "description": "Induction treatment : Lenalidomide 20 mg capsule on days 1 to 21 days of a 28 days cycle for the first cycle followed by 25 mg on daily on days 1 to 21 of a 28 days cycle for cycles 2 to 8 (in the absence of hematologic toxicity. Rituximab at day 1 of each induction course 375 mg/m\u00b2 intravenous.\nMaintenance : Lenalidomide 10 mg capsule on days 1 to 21 days of a 28 days cycle for 1 year or until progression or intolerance."
        }, 
        "brief_summary": {
            "textblock": "Because Primary Central Nervous System Lymphoma (PCNSL) are mainly diffuse large B-cell\n      lymphoma of the activated B cells (ABC) type, the investigators hypothesize that the synergy\n      of lenalidomide with rituximab shown in systemic non-Hodgkin's lymphoma (NHL) could be\n      observed in PCNSL.\n\n      This study will assess the efficiency of the the combination of lenalidomide and rituximab\n      in relapsed/refractory PCNSL, and the efficiency of a maintenance treatment with\n      lenalidomide alone in maintaining the response."
        }, 
        "brief_title": "Efficacy of Lenalidomide With Rituximab in Refractory or Relapse of Primary Central Nervous System Lymphoma", 
        "completion_date": {
            "#text": "May 2018", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Lymphoma", 
            "Relapse", 
            "Lenalidomide", 
            "Rituximab"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Lymphoma", 
                "Recurrence"
            ]
        }, 
        "detailed_description": {
            "textblock": "The investigators use a two-stage Fleming's design based on the following hypotheses under\n      treatment: 10% (null hypothesis, minimal clinical benefit rate), 30% (alternative\n      hypothesis, acceptable clinical benefit rate), 3% type I error rate, 5% type II error rate.\n      Under these hypotheses, a total of 45 assessable patients will be necessary: 22 for the\n      first stage + 23 for the second stage.\n\n      Stage 1: following the inclusion of the first 22 assessable patients, if 0 or 1 patient has\n      an objective response (CR, Complete Response + uCR, unconfirmed Complete Response + PR,\n      Partial Response) at the end of induction treatment, the study would be terminated early and\n      the treatment will be considered ineffective. If 2 or more patients have an objective\n      response at the end of induction treatment, then the treatment will be considered as\n      effective in this indication. Otherwise, the second group of 23 patients will be recruited.\n\n      Stage 2: if at the end of recruitment, 8 or less patients have an objective response, the\n      investigators will conclude to inefficacy, and if 9 or more patients have an objective\n      response, then the treatment will be considered as effective and need further exploration."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients over 18 years old with a refractory or relapse PCNSL and who have previously\n             received at least high dose methotrexate (> 1.5 g/m\u00b2) and high dose cytarabine (2\n             g/m\u00b2)\n\n          -  Patients can have received radiotherapy or intensive chemotherapy with hematopoietic\n             stem cell rescue as part of treatment of the PCNSL or IOL\n\n          -  Patients over 18 years old with a refractory or relapse IOL (Intra Ocular Lymphoma)\n             and who have received either intravenous high dose methotrexate (> 1.5 g/m2) or\n             intraocular methotrexate\n\n          -  Life expectancy > 2 months\n\n          -  Able to swallow capsules (stomach tube not allowed)\n\n          -  Adequate bone marrow function with absolute leukocytes > 2000/mm3, neutrophil count\n             (ANC) > 1000/mm3, haemoglobin > 8 g/dl and platelets > 100 000/mm3\n\n          -  Adequate hepatic function with AST (aspartate aminotransferase) or ALT (alanine\n             aminotranferase) < 3 times the upper limit of normal (ULN), bilirubin < 1.5 x ULN\n             (except in cases of haemolytic anemia or Gilbert's syndrome)\n\n          -  Calculated creatinine clearance > 40 ml/min. Patients with calculated creatinine\n             clearance between 40 and 50ml/min lenalidomide dose will be adjusted as follows (10mg\n             once daily)\n\n          -  Patient aged 18 years old or more and without measure of legal protection\n\n          -  Able to understand teratogenic risks of the treatment\n\n          -  Females of childbearing potential (FCBP) must agree to use two reliable forms of\n             contraception simultaneously or to practice complete abstinence from heterosexual\n             contact during the following time periods related to this study and for at least 4\n             weeks after discontinuation treatment with lenalidomide and one year after cessation\n             of treatment with rituximab. Pregnancy test (\u03b2HCG amount) must be negative at the\n             inclusion and during the study. Men must agree not to procreate a child and use\n             condoms if their partner can procreate, during all the treatment period including any\n             interruption of catches and 4 weeks after the end of treatment.\n\n          -  Signed inform consent\n\n        Exclusion Criteria:\n\n          -  Any severe infection and/or active (eg tuberculosis, sepsis and opportunistic\n             infections), immune deficiency and hypersensitivity to any drug contained in the\n             chemotherapy regimen or to any of their excipients (including lactose intolerance\n\n          -  T-cell lymphoma\n\n          -  Diagnosis of any second malignancy within the last 5 years\n\n          -  Prior history of organ transplantation or other cause of severe immunodeficiency\n\n          -  History of cardiac and /or impaired cardiac function disorders (ECG QTc (corrected QT\n             interval)>450 msec, congenital long QT syndrome, history of ventricular\n             tachyarrhythmias, ventricular fibrillation or simply \"torsade\", congestive heart\n             failure NYHA (New York Heart Association)III/IV, uncontrolled hypertension)\n\n          -  Known HIV infection or active hepatitis B or HCV (hepatitis C virus) infection of\n             less than 4 weeks\n\n          -  Inclusion in another experimental anti-cancer drug therapy\n\n          -  Impossibility to follow the calendar of exams because of geographic, social or\n             psychological reasons\n\n          -  Patient under guardianship\n\n          -  No social security"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "45", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 24, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01956695", 
            "org_study_id": "IC 2012-05", 
            "secondary_id": "2012-003786-17"
        }, 
        "intervention": [
            {
                "arm_group_label": "Lenalidomide & Rituximab", 
                "intervention_name": "Lenalidomide", 
                "intervention_type": "Drug", 
                "other_name": "Revlimid\u00ae"
            }, 
            {
                "arm_group_label": "Lenalidomide & Rituximab", 
                "intervention_name": "Rituximab", 
                "intervention_type": "Drug", 
                "other_name": "Mabthera\u00ae"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Rituximab", 
                "Thalidomide", 
                "Lenalidomide"
            ]
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "April 7, 2014", 
        "location": [
            {
                "contact": {
                    "email": "cchabrot@chu-clermontferrand.fr", 
                    "last_name": "C\u00e9cile Molucon-Chabrot, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Clermont-Ferrand", 
                        "country": "France", 
                        "state": "Auvergne", 
                        "zip": "63003"
                    }, 
                    "name": "CHU Estaing"
                }, 
                "investigator": {
                    "last_name": "C\u00e9cile Molucon-Chabrot, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "emmanuel.gyan@univ-tours.fr", 
                    "last_name": "emmanuel gyan, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Tours", 
                        "country": "France", 
                        "state": "Centre", 
                        "zip": "37044"
                    }, 
                    "name": "CHU Bretonneau - Centre Henry Kaplan"
                }, 
                "investigator": {
                    "last_name": "Emmanuel Gyan, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "a.schmitt@bordeaux.unicancer.fr", 
                    "last_name": "Anna Schmitt, Phd"
                }, 
                "facility": {
                    "address": {
                        "city": "Bordeaux", 
                        "country": "France", 
                        "state": "Gironde", 
                        "zip": "33076"
                    }, 
                    "name": "Institut Bergoni\u00e9"
                }, 
                "investigator": {
                    "last_name": "Anna Schmitt, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "sylvain.choquet@psl.aphp.fr", 
                    "last_name": "Sylvain Choquet, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Paris", 
                        "country": "France", 
                        "state": "Ile de France", 
                        "zip": "75013"
                    }, 
                    "name": "H\u00f4pital de la Piti\u00e9 Salp\u00e9tri\u00e8re"
                }, 
                "investigator": {
                    "last_name": "Sylvain Choquet, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "carole.soussain@curie.net", 
                    "last_name": "Carole Soussain, MD", 
                    "phone": "+33147111515"
                }, 
                "facility": {
                    "address": {
                        "city": "Saint-Cloud", 
                        "country": "France", 
                        "state": "Ile de France", 
                        "zip": "92210"
                    }, 
                    "name": "Institut curie - H\u00f4pital Ren\u00e9 Huguenin"
                }, 
                "investigator": {
                    "last_name": "Carole Soussain, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "RGressin@chu-grenoble.fr", 
                    "last_name": "R\u00e9my Gressin, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Grenoble", 
                        "country": "France", 
                        "state": "Is\u00e8re", 
                        "zip": "38043"
                    }, 
                    "name": "Chu Michallon"
                }, 
                "investigator": {
                    "last_name": "R\u00e9my Gressin, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "p.beauchesne@chu-nancy.fr", 
                    "last_name": "Patrick Beauchesne, MD", 
                    "phone": "+331383851688"
                }, 
                "facility": {
                    "address": {
                        "city": "Nancy", 
                        "country": "France", 
                        "state": "Lorraine", 
                        "zip": "54036"
                    }, 
                    "name": "H\u00f4pital Central"
                }, 
                "investigator": {
                    "last_name": "Pactrick Beauchesne, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "franck.morschhauser@chru-lille.fr", 
                    "last_name": "Franck Morschhauser, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Lille", 
                        "country": "France", 
                        "state": "Nord", 
                        "zip": "59037"
                    }, 
                    "name": "CHRU Lille - H\u00f4pital Claude Huriez"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "herve.ghesquieres@lyon.unicancer.fr", 
                    "last_name": "Herv\u00e9 Ghesqui\u00e8res, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Lyon", 
                        "country": "France", 
                        "state": "Rh\u00f4ne-Alpes", 
                        "zip": "39373"
                    }, 
                    "name": "Centre L\u00e9on B\u00e9rard"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "fabrice.jardin@chb.unicancer.fr", 
                    "last_name": "Fabrice Jardin, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Rouen", 
                        "country": "France", 
                        "state": "Seine Maritime", 
                        "zip": "76038"
                    }, 
                    "name": "Centre Henri Becquerel"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "damaj.gandhi@chu-amiens.fr", 
                    "last_name": "Ghandi Laurent Damaj, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Amiens", 
                        "country": "France", 
                        "state": "Somme", 
                        "zip": "80054"
                    }, 
                    "name": "CHU Amiens -H\u00f4pital Sud"
                }, 
                "investigator": {
                    "last_name": "Gandhi Damaj, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "France"
        }, 
        "number_of_arms": "1", 
        "official_title": "Phase II Study Evaluating the Efficacy of Lenalidomide in Association With Rituximab in Refractory or Relapse of Primary Central Nervous System Lymphoma (PCNSL)", 
        "other_outcome": {
            "description": "Pilot exploration of T cells and NK cells populations in PCNSL before and after treatment with the combination of lenalidomide-rituximab and to correlate possible changes of these populations with therapeutic response", 
            "measure": "Exploration of T cells and NK (Natural Killer) cells populations in PCNSL before and after treatment to correlate possible changes of these populations with therapeutic response", 
            "safety_issue": "No", 
            "time_frame": "33 months"
        }, 
        "overall_contact": {
            "email": "patricia.tresca@curie.net", 
            "last_name": "Patricia TRESCA, UGEC Leader", 
            "phone": "33156245630"
        }, 
        "overall_contact_backup": {
            "email": "isabelle.turbiez@curie.net", 
            "last_name": "Isabelle TURBIEZ, Project Manager", 
            "phone": "33147111659"
        }, 
        "overall_official": {
            "affiliation": "Institut Curie - Hopital Rene Huguenin", 
            "last_name": "Carole SOUSSAIN, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "France : ANSM - National Safety Agency of Medicines and Healths Products", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "August 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The objective response rate (CR+uCR+PR) will be evaluated according to the IPCG (International Primary CNS lymphoma Collaborative Group) recommendations. Patients will have an cerebral MRI, an ophthalmological examination and a lumbar puncture at several times.", 
            "measure": "Assess the efficacy of lenalidomide in combination with rituximab in relapsed/refractory PCNSL as measured by the objective response rate (CR + uCR + PR) at the end of the 8 cycles of induction therapy.", 
            "safety_issue": "No", 
            "time_frame": "33 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01956695"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "The safety of the association during induction and maintenance therapy in a population of PCNSL (NCI V4)", 
                "safety_issue": "Yes", 
                "time_frame": "56 months"
            }, 
            {
                "measure": "The duration of response", 
                "safety_issue": "No", 
                "time_frame": "56 months"
            }, 
            {
                "measure": "Progressive Free Survival at one year from the date of inclusion to the date of progression of the disease or death", 
                "safety_issue": "Yes", 
                "time_frame": "56 months"
            }, 
            {
                "measure": "Overall Survival from the date of inclusion to the date of death", 
                "safety_issue": "Yes", 
                "time_frame": "56 months"
            }, 
            {
                "measure": "Quality of life using QLQ-C30 EORTC (European Organization for Research and Treatment of Cancer) questionnaire", 
                "safety_issue": "No", 
                "time_frame": "20 months"
            }
        ], 
        "source": "Institut Curie", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "Centre Hospitalier Universitaire, Amiens", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Institut Bergoni\u00e9", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "University Hospital, Clermont-Ferrand", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "University Hospital, Lille", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Central Hospital, Nancy, France", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Groupe Hospitalier Pitie-Salpetriere", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Centre Henri Becquerel", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "University Hospital, Tours", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Centre Leon Berard", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "University Hospital, Grenoble", 
                    "agency_class": "Other"
                }
            ], 
            "lead_sponsor": {
                "agency": "Institut Curie", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "August 2013", 
        "study_design": "Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "September 2013"
    }
}